The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical in vitro and in vivo evaluation of antitumor activity of poly (ADP-ribose) polymerase inhibition and trastuzumab combined therapy in HER2-overexpressing breast cancer.
Ignacio Tusquets
No relevant relationships to disclose
Jetzabel Garcia-Parra
No relevant relationships to disclose
Alba Dalmases
No relevant relationships to disclose
Beatriz Morancho
No relevant relationships to disclose
Oriol Arpi
No relevant relationships to disclose
Silvia Menendez
No relevant relationships to disclose
Mohammad Ali Sabbaghi
No relevant relationships to disclose
Sandra Zazo
No relevant relationships to disclose
Cristina Chamizo
No relevant relationships to disclose
Juan Madoz
No relevant relationships to disclose
Pilar Eroles
No relevant relationships to disclose
Sonia Servitja
No relevant relationships to disclose
Jose Yelamos
No relevant relationships to disclose
Ana Lluch
No relevant relationships to disclose
JoaquÃÂn Arribas
No relevant relationships to disclose
Federico Rojo
No relevant relationships to disclose
Ana Rovira
No relevant relationships to disclose
Joan Albanell
No relevant relationships to disclose